SCHEMBL3010895

SCHEMBL3010895

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(OC)ccc4OC)CC3)n2)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
GAA P10253 2/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 2/20 0.37
RECQL P46063 1/20 0.37
NPC1 O15118 1/20 0.37
F2RL3 Q96RI0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011425 0.95 MAPT (0.39) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3006435 0.94 MAPT (0.38) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3014447 0.94 ALDH1A1 (0.43) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3013075 0.94 MAPT (0.40) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3011978 0.93 ALDH1A1 (0.44) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3017810 0.91 ALDH1A1 (0.40) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL2997817 0.90 ALDH1A1 (0.47) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3018728 0.90 ALDH1A1 (0.43) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3020230 0.89 KDM4E (0.42) MAPTALDH1A1HPGDHSD17B10RAB9A
SCHEMBL15671708 0.89 ALDH1A1 (0.44) MAPTALDH1A1HPGDHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885HPGD 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.